Auspex is a clinical stage biotechnology company focused on the discovery and development of novel therapeutics based on site-specific deuteration of promising drug candidates and clinically validated drugs.
The deuteration technology can generate potential therapeutics while reducing risk, time and cost of drug development, Auspex said.
The discovery and initial development of the program subject to this transaction was conducted at Auspex Pharmaceuticals.
Auspex COO Andreas Sommer said deuterium is a non-radioactive isotope of hydrogen that has been demonstrated to generate new chemical entities with unique and beneficial properties.
"This agreement demonstrates Auspex’s ability to build on its strong intellectual property position across multiple therapeutic areas," Sommer said.
Auspex acting CEO and partner at Thomas McNerney & Partners Pratik Shah said it is a reflection of their efforts to provide access to novel deuterated drugs that address significant market opportunities.